Method of treating visceras
SUBSTANCE: invention relates to medicine, namely to methods of treating diseases of various aetiologies and injuries of various visceras. Electropunctural pre-examination aims at determining the patient's overall potential and the potential in a point on the body surface at a minimal distance from the viscera to be treated, or in its immediate projection tender zones. A stem cell growth area is stimulated by placing a bee within the sternum. Then, an irritation centre is created using vacuum- or hirudotherapy in a point on the body surface at a minimal distance from the above viscera or in its immediate projection tender zones. The irritation centre is created to be intensive and short-term at the level of the potential in the point below the overall potential, or to be weak and long-term at the level of the potential in a point above the overall potential.
EFFECT: method provides the effective local therapeutic effect on the involved visceral tissues ensured by a combination of the used components of the effect.
2 cl, 3 ex
The invention relates to medicine, namely to methods of treatment of different diseases and injuries of various organs.
There is a method of treatment of different diseases and injuries of various organs using mesenchymal stem cells (MSCS) or their differentiated progeny (see patent RU 2301667, IPC A61K 31/195, A61K 35/28, A61P 43/00). MSC injected in cultures derived from autologous or neautrogena human tissue, intravenously or directly into the affected organ or on its surface. After this the patient intramuscularly or on the skin surface impose drug metaprogram or its chemical analogue: 2-(3'-dimethylaminopropyl)-5-methylhexan-4-OIC acid or 2-(3'-dimethylaminopropyl)-5,9,13-trimethylacetamido-4,8,12-OIC acid. The method provides an improvement of results of treatment by accelerating the healing process, even when using minimal doses of metoprolol or its counterpart, the gain distribution in the affected tissues intensively proliferating cells.
However, in this method, the stem cells are injected invasive, which can lead to immune response.
There is a method of treatment of traumatic lesions of the spinal cord, applicable in neurosurgery for the treatment and rehabilitation of patients with persistent neurological defic the volume after trauma to the spinal cord (see the patent RU 2286160, IPC A61K 35/28, A61P 25/00). The method includes the transplantation of bone marrow stem cells, which use of autologous mononuclear bone marrow cells of the patient. After 24-hour incubation, the cells are divided into two factions. The fraction of cells adherent to plastic injected into the cavity emptied intramedullary cysts in the amount not exceeding the size of the cavity of the cyst, and the fraction of cells adherent to plastic, is injected. The method can reduce the severity of neurological deficits in patients in remote and late period of traumatic disease of the spinal cord due to the complex influence on the repair of nervous tissue of all types of stem cells, which differentiate into neuronal direction directly in the body of the patient without prolonged cultivation in vitro.
However, this method involves a long procedure incubation of cells; and besides, he has all of the disadvantages associated with the introduction of invasive cells.
Known biotransplant and method for the treatment of parkinsonism (see patent RU 2259836, IPC A61K 35/30, A61K 35/48, A61P 25/16). Biotransplant for the treatment of parkinsonism contains the active ingredient: the culture of genetically unmodified neuronal stem cells (NSC)derived from the forebrain tissue is of human embryos in the 1st trimester of pregnancy or periventricular areas of the brain 15 to 20 weeks of gestation and selectively propagated in culture conditions to the number 107-109 pluripotent undifferentiated cells as part of neurostar, when the content of the CLAIM 50-500 million, and 2 ml of physiological solution. A method of treating Parkinson's disease include the introduction of the patient endolyumbalno 50-500 million NSC in 2 ml of physiological solution, simultaneously. The proposed biotransplant and a method of treating parkinsonism quickly to restore and improve function of affected brain and reduce the duration of treatment, and also provides a more stable and long-lasting effect.
However, in this method using human embryos, which is contrary to the norms of humanity and morality.
The closest is a method of targeted delivery of stem cells in the treatment of optic nerve atrophy of various etiologies (see patent RU 2375019, IPC A61F 9/007, A61K 35/28, A61P 27/02). Spend vitrectomy, remove the back of the hyaloid membrane, with the nasal side of the optic nerve perform radial optical neurotomy (RON). Conducting radial optical neurotomy from the nasal side of the optic nerve creates a depot for targeted delivery of mesenchymal stem cells in the optic nerve and improves volumetric blood flow velocity in the optic nerve in the dissection of the laminar plates and expansion of the scleral canal, the occurrence of chorioretinal anastomoses in the postoperative period. Immediately after RO is formed in the channel administered 0.05 ml of autologous cultured mesenchymal stem cells from bone marrow of the patient. Intravitreal (into the vitreal cavity of the eye) injection of autologous cultured MSC bone marrow of the patient in the channel RON accompanied by their selective adhesion in this area, which contributes to the activation of reparative processes due to engraftment of transplanted stem cells in the damaged areas with the consequent proliferation and differentiation of both transplanted and resident stem cells.
The disadvantage of this method is the necessity of surgical intervention in the patient, the complexity of the procedure, including the cultivation of autologous stem cells in vitro, as well as the lack of control the relationship between the body's need for stem cells and the amount introduced into the body cells.
The task of the claimed invention is to provide selective therapeutic effects.
The technical result is to increase the effectiveness of treatment by providing a local therapeutic effect.
This technical result is achieved by the fact that, according to the claimed method of treatment, pre-electroacupuncture at the examination determine the overall potential of the body of the patient and the potential at a point on the body surface at a minimum distance from the body requiring treatment, or is it the nearest flat area Zakharyin-Ged on the skin, stimulate the growth zone of the stem cells according to the method Muzalevskaya by raising bees in the sternum, and then create a focus of irritation with the use of vacuum or occupational therapy at a point on the body surface at a minimum distance from the specified authority or its nearest projection area Zakharyin-Ged on the skin, while the focus of intense irritation and transient when the level of the potential at a point below the total capacity, or weak and long at the level of the potential at a point higher than the common potential. Pre spasms and improve blood flow to the tissues of the body requiring treatment.
The inventive method includes the following procedures.
1. Diagnosis the delivery of stem cells.
Carry out diagnosis of the body, measuring the potentials at the test points according to the method Muzalevskaya (RF patent for the invention №2177776). First, determine the total capacity of the patient's body by measuring the conductivity (or electrical resistance) by any known method or device designed for electric diagnostics by R. Voll, for example, with industrial output device "VEDA-903": "Electro-diagnostic apparatus of the General practitioner, homeopath and family doctor". This indicator is cleared when the electro-examination iyavlyaetsya assessment criterion for further diagnostics (see Passport, technical description and operating instructions "VEDA-903", p.18). By registering readings when the connection is connected to the device of the active electrode with the palm of the left hand of the patient, and a passive electrode, with the palm of the right hand determine the average values of the total conductivity of a man (the total capacity of the body), which are within 78-82 dimensionless units. Next, perform a measurement of potentials in the individual control points located on the body surface at a minimum distance from the body (target)requiring treatment or in its immediate projection area Zakharyin-Ged on the skin. The potential is measured by connecting the active electrode with the control point.
If necessary, provide training to the treatment of body tissues in the delivery of stem cells. Typically, unhealthy body is in shock, spasm, so after it is identified, conduct preparatory therapy to relieve spasms and normalization of blood flow through the body. Examples preparatory therapy can be massage, finger, objavljivanje, drug withdrawal spasms, in addition to antispasmodic action have procedures vacuum and hirudotherapy.
2. Stimulation of the production of stem cells in the human body
To stimulate the production and in the human body necessary for tissue repair in the number of stem cells are leeching or apitherapy the chest on the way Muzalevskaya (RF patent for the invention №2417052). Reflex effects of exercise on the area of the sternum using gerudo and/or apitherapy. Prior to exposure to carry out measurement and calculation of the averaged potential of the front part of the body except for the area of the sternum, namely at the points of small pelvis in the center, right, left, in place of the projection above the kidney, liver, stomach, pancreas, gall bladder. Separately provide measurements of the potential area of the sternum in the points situated on the middle line in the center arm of the sternum, at the level of the fourth rib of the body of the sternum and in the area of the xiphoid process. Then reveal the variation of potential in the area of the sternum from the average values of potential the front, and identifying reduction potential values of the area of the sternum relative to the averaged value of the potential of the front part of the body carry the impact of a leech or a bee on the sternum area not more than 3 minutes with a control measurement of potentials. The effect is repeated until the alignment of the values of the potentials or exceeding the value of the potential of the sternum above the average value of the potential of the front part of the body. When implementing the method using no more than 5 leeches on 1 session or 1-3 bees, leaving the stinger in the time from 20 seconds to 3 minutes. The number of repeated impacts depends on the condition of the patient.
3. And the targeted delivery of stem cells.
When focusing the impact of stem cells on the body (target), characterized by a control point with the value of a potential lower than the total capacity of the patient, at this point create foci of irritation by short-term (up to three minutes)but intense vacuum or hirudotherapy. When focusing effects on the body, the potential value of the corresponding point which is higher than the common potential of the patient, at this point create foci of irritation by prolonged (three to thirty minutes), but a weak vacuum or occupational therapy. Irritation helps to increase blood flow and microcirculation in the field of application of therapeutic effects, and establishing targets for attracting produced in the body's stem cells to the affected area. Thus, it is possible to achieve maximum local concentration of intrinsic stem cells of the patient in therapeutic effect and, accordingly, high restorative effect of damaged organs from the effects of stem cells.
Industrial applicability with the achievement of the technical result of the claimed invention is illustrated by the following examples of clinical trials.
Example 1. The patient LWP, 59 years old.
In June 2011 pproviding ultrasound of internal organs. The diagnosis of hepatomegaly, fatty infiltration p is Chaney (point form) chronic cholecystitis (stagnant bile), chronic pancreatitis (microcavities), minor venous congestion of the kidneys. Conducted stimulation zone growth of stem cells apitherapy with a focus on the region of the liver and kidneys vacuum therapy and leeching - conducted 5 sessions a day. For the selection of exposure modes previously conducted measurements of biopotentials in the areas of production of cans and leeches method Muzalevskaya. On the edge of the costal arch to the right potentials were increased, so the effect was implemented to reduce potential weak excitation lasting more than ten minutes (on brake method). In the kidneys from behind potentials have been reduced, so the effect was implemented for capacity building - strong excitation with duration of up to three minutes (according to the method of excitation).
The 1st session. To encourage the patient's stem cells held apitherapy - one bee was placed in the region of the sternum to the point with the lowest potential for thirty seconds. To focus the impact of stem cells on liver spent occupational therapy five leeches on the edge of the costal arch to the right before saturation. To focus the impact of stem cells on the kidneys spent vacuum-therapy - using two cans (one Bank for each kidney) execute and strong impact on the kidneys back within three minutes.
The 2nd session. Stimulate the body's production of the patient's stem cells at the first session. To focus the impact of stem cells on liver spent vacuum-therapy - with three cans made little impact on the edge of the costal arch to the right for more than ten minutes. To focus the impact of stem cells on the kidneys spent hirudotherapy - two leeches on two sides on the kidneys back within three minutes.
3rd session. Stimulate the body's production of the patient's stem cells at the first session. To focus the impact of stem cells on liver spent vacuum-therapy - with three cans made little impact on the edge of the costal arch to the right for more than ten to twelve minutes. To focus the impact of stem cells on the kidneys spent vacuum-therapy - using two cans (one Bank for each kidney) made a strong impact on the kidneys back within three minutes.
4th session. The same as in the first session.
5th session. Same as in the second session.
After two months of repeated ultrasound. Diagnosis: chronic cholecystitis in remission, chronic pancreatitis, kidney pathologies it is not revealed. Thus, there are clear signs of improvement of ultrasound data. Feeling patsie the TA has improved.
Example 2. The patient VBA, 56.
Diagnosis: benign prostatic hyperplasia 1-2 degrees on the background of calculous prostatitis. In 2009, the stimulation of the growth zone stem cells without focusing effects of stem cells on delivery. There is General improvement, has improved the condition of internal organs. Changes of the prostate were observed. In 2010, held three sessions of stimulation zone growth of stem cells with a focus on the impact of stem cells on the prostate gland.
The 1st session. Stimulate the body's production of the patient's stem cells, which held apitherapy - two bees per minute in the sternum area. To focus the impact of stem cells on the prostate gland spent vacuum-therapy - severe agitation up to three minutes in the sacrum and in the suprapubic area, as well as leeching four leeches on the coccyx and three leeches PA crotch before saturation.
The 2nd session. Stimulate the body's production of the patient's stem cells at the first session. To focus the impact of stem cells on the prostate gland spent hirudotherapy - four leeches in the rectal area before saturation, and vacuum-therapy - severe agitation up to three minutes in the suprapubic area.
3rd session. Stimulated production is in the patient's stem cells at the first session. To focus the impact of stem cells on the prostate gland spent hirudotherapy three leeches in the suprapubic area to saturation, as well as vacuum-therapy - weak agitation for ten minutes in the rump.
Repeated ultrasound control after 5 months showed decrease swelling of the prostate gland, a significant positive trend; hyperplasia of 1 degree.
Example 3. The patient BNW, 60.
The diagnosis of hepatomegaly, moderate diffuse changes of the liver parenchyma (lipomatosis steatosis), chronic cholecystitis (Zamoskvoretskaya bile), chronic pancreatitis, diffuse changes in the pancreas.
The 1st session. Stimulate the body's production of the patient's stem cells, which held apitherapy - one bee was placed in the sternum area for thirty seconds. To focus the impact of stem cells on liver spent hirudotherapy - five leeches on the edge of the costal arch to the right before saturation.
The 2nd session. Stimulate the body's production of the patient's stem cells, which held apitherapy - one bee was placed in the sternum area for two minutes. To focus the impact of stem cells on the pancreas spent hirudotherapy three leeches to saturation at the surface of the body in the area of the projection of the pancreas.
3rd session. Stimulated exp is processing the patient's stem cells, what held apitherapy - two bees were placed in the sternum area for two minutes. To focus the impact of stem cells on liver spent hirudotherapy three leeches on the edge of the costal arch to the right before saturation. To focus the impact of stem cells on the pancreas spent hirudotherapy two leeches before saturation on the surface of the body in the area of the projection of the pancreas.
After four and a half months in the ultrasound revealed signs of chronic congestive cholecystitis, chronic pancreatitis. A significant positive trend.
1. The method of treatment of internal organs, wherein the pre when electro-examination determine the overall potential of the body of the patient and the potential at a point on the body surface at a minimum distance from the body requiring treatment, or in its immediate projection area Zakharyin-Ged on the skin, stimulate the growth zone of the stem cells according to the method Muzalevskaya by raising bees in the sternum, and then create a focus of irritation with the use of vacuum or hirudotherapy at a point on the body surface at a minimum distance from the specified authority or its nearest projection area Zakharyin-Ged on the skin, when this is the focus of intense irritation and kratkofil the config when the potential level at the point of common potential or weak and long at the level of the potential at a point higher than the common potential.
2. The method according to claim 1, wherein the pre spasms and improve blood flow to the tissues of the body requiring treatment.
SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of benign hyperplasia of prostate gland. For this purpose dynamic examination of prostate gland is carried out before drug therapy and 3, 6 and 9 months after that. Dynamic examination includes transrectal ultrasound examination (TRUSE) with Dopplerography and sonoelastography (SEG) of prostate gland. Comparison of prostate size values, hyperplasia size, blood flow in capsular and parauretral arteries, blood flow in adenomatous nodes and density of transitory zones of prostate is carried out in SEG. If values of examined parameters by TRUSE data decrease by 15% and more, each parameter is given 1 point. If density of transitory zones of prostate in sonoelastography is higher than 35 KPa, 1 point is given too. As a result if the sum is not less than 4 points, conservative therapy is stopped. If the sum of points is less than 4 points, therapy is continued. Examination is repeated after next 3 months.
EFFECT: method ensures reduction of terms of drug treatment and increase of treatment quality due to possibility of determining indications for complete or partial cancellation of drug treatment within 3-6 months.
1 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is using at least one protease for producing a drug preparation for treating and/or preventing benign prostatic hypertrophy/hyperplasia wherein the drug preparation is acceptable for the oral administration with at least one protease being specified in a group consisting of plant and microorganism proteases, and with at least one protease being administered in the amount of 1 to 100 mg/kg of body weight, and a respective pharmaceutical preparation.
EFFECT: what is shown is reducing high vascular endothelial growth factor in patient's blood under the action of a mixture of enzymes that makes it possible to inhibit angiogenic growth factors (VEGF), thereby leading to lower vascularisation, and reducing benign prostatic hypertrophy/hyperplasia, with the enzymatic therapy under the present invention having no effect on the normal VEGF level.
13 cl, 7 dwg
SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating suppurative septic complications of prostate adenoma. For this purpose, with underlying administering antibiotics, ozonised saline solution in the concentration of 3 to 6 mg/l in the amount of 200 to 400 ml is additionally intravenously administered; the therapeutic course is 3-5 injections depending on the patient's state. Besides, ozonised saline solution in the concentration of 5 to 8 mg/l is injected into the bladder in the preoperative preparation period, and from the second postoperative day, saline solution is introduced drop-by-drop in the amount of 400.0 ml daily five times with a two-way flushing system.
EFFECT: method enables reducing the risk of urosepsis, eliminating intoxication and accelerating postoperative wound healing of a BPH bed by anti-inflammatory, detoxification, analgesic action, improved blood rheology and microcirculation, increased local immunity with activated regenerative and reparative processes.
2 tbl, 1 ex
SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.
EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.
28 cl, 233 ex, 29 tbl
SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of chronic abacterial prostatitis in men, which is not connected with dysfunction of urethral sphincter. For this purpose, efficient amount of fispemiphene is introduced to patient who needs it. Introduction of fispemiphene is performed in amount in the range from 0.1 to approximately 100 mg/kg of body weight.
EFFECT: invention ensures efficient treatment of abacterial prostatitis at the early stage of disease where only histological changes of prostate gland are present without presence of urethral sphincter dysfunction, with drug fispemiphene, which demonstrates antagonistic activity to estrogen receptors in particular with respect to prostate tissue.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutical industry, in particular to composition, which contains epigallocatechine-3-gallate as active component and target additive. Pharmaceutical composition for peroral introduction, which contains epigallocatechine-3-gallate and block-copolymer of oxyethylene and oxypropylene, in which content of hydrophobic block constitutes not less than 50 wt %, and molecular weight of hydrophilic block constitutes 2250 Dalton and not more, with specified weight ratio of epigallocatechine-3-gallate and block copolymer 1:1-10:1. Application of upper described pharmaceutical composition for treatment of atopic dermatitis, Crohn's disease, adenomyosis, and hyperplastic diseases of prostate.
EFFECT: composition has increased bioavailability in peroral application, improves absorption of active compound epigallocatechine-3-gallate in blood flow.
6 cl, 2 dwg, 4 tbl, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmacy, namely technology of preparation of rectal suppositories. The suppositories with solid licorice extract consist of solid licorice extract 0.75 g on a hydrophilic base, polyethylene glycol 6000 1.25 g and polyethylene glycol polystear 0.25 g.
EFFECT: making the preparations exhibiting anti-inflammatory action, and also a positive effect on the hormonal status and the copulative function.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) which is selected from gentisate, maleate, citrate, fumarate and semitartrate salts, which possess improved properties in their application, in particular higher stability.
EFFECT: invention also relates to method of obtaining acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) and to pharmaceutical composition, containing them, for treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive lung disease, benign prostate gland hypertrophy and diseases of lower urinary tract.
11 cl, 30 ex, 7 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: declared group of inventions relates to medicine. There are declared methods of treatment and preventive treatment of prostate cancer in males and a method for treatment of prostate cancer in male dogs involving a single agent therapy in the form of introducing a therapeutic amount of N,N'-bis(2,3-butadienyl)-1,4-butane-diamine or its pharmaceutically acceptable salt or solvate. The therapeutic amount is specified within the range from 1-100 mg/kgbody weight and dosed within the range from twice a week to once a day.
EFFECT: group of inventions has high therapeutic efficacy.
26 dwg, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to coated pharmaceutical formulations with a controlled-release active substance and to the use thereof for treating benign prostatic hyperplasia. The formulation contains a therapeutically effective amount of the active substance representing tamsulosin or its pharmaceutically acceptable salt encapsulated in a granulated core, and an insoluble permeable polymer found both in the granulated core and in the coating. Said pharmaceutical formulations may also contain a surfactant and other optional excipients. Besides, the invention refers to a method for preparing the pharmaceutical formulations which involves mixing core ingredients, granulating, pressing and shaping in a sphere, drying and coating.
EFFECT: invention provides the formulations with pH-independent release of the active substance, low inter-individual variability and low biological variability.
14 cl, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to therapy of internal non-infectious diseases, particularly to compositions for preventing and treating liver dystrophy in cattle. An agent for preventing and treating liver dystrophy in cattle contains an antihepatotoxic serum and an antispleenotoxic serum; the serums are pre-processed in acidic and enzymatic hydrolysis at pH 3.9-4.0 and pepsin concentration 49-51 mg per protein 100 g for 17.5-18.5 hours at temperature 37-38°C; then hydrolised serums are mixed with sterile saline, preserved phenol concentrated 0.4-0.5% at 1.0 ml thereof, the antihepatotoxic serum - 9.0-11.0 titre units and the antispleenotoxic serum - 9.0-11.0 titre units.
EFFECT: invention enables more effective prevention and treatment of the liver dystrophy in cattle, higher production rate.
1 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a synergetic preparation for treating cardiovascular insufficiency, types I and II diabetes mellitus, hepatobiliary diseases, containing a combination of a pharmaceutically acceptable salt of 2-ethyl-6-methyl-3-pyridin-3-ole and taurin in the amount of 2-75% and pharmaceutically acceptable carriers, excipients and additives with the mass ratio of the active ingredients of the combination making 9:1 to 1:9. The preparation may be presented in the form of a tablet, a capsule or a solution for injections. The invention also refers to a method of treating cardiovascular insufficiency, types I and II diabetes mellitus, hepatobiliary diseases wherein the therapeutically effective amount of the synergetic preparation is administered to the patient.
EFFECT: preparations possess the higher efficacy as compared to the common analogues.
5 cl, 7 tbl, 7 ex
SUBSTANCE: present group of inventions refers to medicine, namely therapy, and concerns treating fibrotic diseases. That is ensured by administering 40-O-(2-hydroxy)ethylrapamycin or a pharmaceutical composition thereof in the effective amount.
EFFECT: administering the above compound provides slowing of the hepatic fibrosis development, including following liver transplantation with underlying immunosuppressive therapy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical composition for preventing and treating diseases mediated by high expression or high activity of liver X receptor (LXRa), high expression or high activity of a sterol regulatory element-binding protein-1c (SREBP-1).
EFFECT: preventing and treating renin hypertension, hyperaldosteronism, adrenoleukodystrophy, glomerular sclerosis, proteinuria, nephropathy, hepatic steatosis, hypertriglyceridemia or hyperreninemia, possessing high activity.
6 cl, 11 dwg, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and aims at treating and preventing hepatic encephalopathies. There are presented composite formulations containing various combinations of L-carnitine, acetyl-L-carnitine, succinate, L-glutamate, L-arginine, betaine and creatine phosphate, N-acetylcysteine, coenzyme Q10 and dihydroquercetin; S-adenosylmethionine; coenzyme Q10 and dihydroquercetin, dihydroquercetin and lipoamide.
EFFECT: group of inventions enables relieving behavioural, neurological and psychic disorders by activating the osmoprotective and energetic systems, detoxification reaction systems of ammonium ions and other toxins, as well as the antioxidant systems of cerebral and hepatic cells.
5 cl, 3 ex, 4 tbl, 3 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to organic chemistry and chemistry of natural products, more specifically to a method for preparing a new compound, a 20-hydroxyecdysone derivate conjugated with a short-chain vitamin E analogue, promising for medicine and pharmacology, namely to a method for preparing a 20-hydroxyecdysone conjugate by a reaction thereof with (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)acetaldehyde in ethyl acetate at room temperature in the absence of an acid catalyst (TsOH or phosphonomolybdic acid) for 24 h, debenzylation of the prepared intermediate conjugate in the ethanol solution in the presence of the catalyst Pd-C. The invention also refers to using such compound as an antioxidant agent inhibiting the lipid peroxidation process.
EFFECT: prepared hybride compounds appears to be promising in medicine and pharmacology as the new geroprotective antioxidants.
3 cl, 3 tbl, 3 ex
SUBSTANCE: invention refers to veterinary science, and may be used for dog's hepatosis therapy. The method for dog's hepatosis therapy involves using a hepatoprotector, a microelement and herbal tea; the hepatoprotector is presented by the preparation Ursosan containing 250 mg of ursodeoxycholic acid; the microelement is selenium, and herbal tea is aqueous-alcoholic extract of camomile blossom clusters and birch buds used sequentially orally: Ursosan 10 mg per 1 kg of animal's body weight, selenium 3 mg per 1 kg of animal's body weight, aqueous-alcoholic extract of camomile blossom clusters and birch buds 1 ml per 1 kg of animal's body weight for 30 days every 12 hours.
EFFECT: method enables conducting the effective therapy and prevention of dog's hepatosis ensured by increasing liver resistance to unfavourable effects and an ability to recover the injured hepatic tissue, as well as by avoided allergic reactions on the administered hepatoprotector.
2 cl, 1 tbl
SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be used for treating the lithic stage of cholelithiasis. For this purpose, ursodeoxycholic acid is administered for the night with underlying the mineral water Uvinskaya heated to 40-45°C.
EFFECT: method enables increasing the clinical effectiveness ensured by reducing high lithogenicity of bile with improved gallbladder contractility.
2 cl, 1 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a method for preparing a milk thistle extract having a higher degree of silymarin release. A method for preparing a milk thistle extract, wherein the extract containing 15-85 wt %, particularly 30-65 wt % of silymarin is treated with anhydrous C1-C4 alcohol, optionally filtered and concentrated, then dried and optionally ground, wherein a degree of silymarin release is 80% or higher (versions). The milk thistle extract for treating and preventing liver and gallbladder dysfunctions. A pharmaceutical composition for treating and preventing liver and gallbladder dysfunctions.
EFFECT: extract is characterised by a higher degree of silymarin release and effective for treating and preventing the liver and gallbladder dysfunctions.
8 cl, 3 dwg, 2 ex
SUBSTANCE: invention refers to medicine and aims at treating bile passage dysfunction. What is involved is a 2-staged integrated treatment. At the 1st stage, a diet, sorbents, mineral water, physiotherapy (thermal vibromassage of the area of the gall bladder and liver, or biologically active points) are prescribed. At the 2nd stage, the treatment is prolonged by administering adsorbents in the form of herbal preparations, as well as pelotherapy considering a type of dysfunction.
EFFECT: method enables reducing the length of pain management, prolonging remission or achieving full rehabilitation in children and adolescents suffering bile passage dysfunction and living in environmentally unfriendly regions.
3 cl, 4 ex, 2 tbl
SUBSTANCE: invention refers to medicine, namely to - physiotherapy, balneology. A method involves the exposure to a low-frequency pulse magnetic field. The exposure covers 6 fields. If the exposure covers the 1st and 2nd fields, including paravertebral muscles, the mode B is used. The exposure consists of single pulses of the pulse duration for S inductor 110±10 mcs, for N inductor 260±20 mcs. Pulse length is 16 Hz, and intensity is 70-80%. The inactive N inductor is placed on the side of more evident pain sensations. Length of the exposure is 3 minutes. If the exposure covers the 3rd-6th fields including projections of the gluteus medius muscle and rectus muscle of thigh, the mode A is used. The exposure consists of paired pulses. The pulse duration for S inductor is 110±10 mcs, and for N inductor 260±20 mcs. Intensity is 80-100%. An inter-pulse interval is 40 ms. The active S inductor is placed within a projection of the gluteus medius muscle and rectus muscle of thigh in its lower one-third from the side of the surgically operated joint. The inactive N inductor is placed on a posterior thigh in its lower one-third and a projection of the rectus muscle of thigh in its upper one-third. The exposure length for the 3rd-4th and 5-6th fields makes 3 minutes for each. Total duration of a procedure is 9 minutes. The procedures are daily. The therapeutic course is 10-12 procedures. Pelotherapy by applications of peat mud onto the paravertebral lumbar spine and a projection of hip joints follows 60-90 minutes later. Mud temperature is 38 - 40°C. Duration of a procedure is 20-30 minutes. The procedures are performed every second day. The therapeutic course is 8-10 procedures. The method improves body self-adaptation ensured by optimising the immune system functioning, the lipid peroxidation system and antioxidant protection.
EFFECT: method activates the metabolic processes in joint and periarticular tissues ensured by normalising micro blood flow in the lower extremities.
2 ex, 5 tbl